Advice

in the absence of a submission from the holder of the marketing authorisation:

epoetin alfa (Eprex®) is not recommended for use within NHSScotland.

Indication under review: treatment of symptomatic anaemia (haemoglobin concentration of ≤10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice359KB (PDF)

Download

Medicine details

Medicine name:
epoetin alfa (Eprex)
SMC ID:
SMC2164
Indication:
Treatment of symptomatic anaemia (haemoglobin concentration of ≤10g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL).
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Nutrition and blood
Submission type
Non submission
Status
Not recommended
Date advice published:
11 March 2019